We tested nonmucoid Pseudomonas aeruginosa isolates obtained from cystic fibrosis (CF) patients for the expression of lipopolysaccharide (LPS) serotype antigens, serum sensitivity, and production of mucoid exopolysaccharide (MEP). When all nonmucoid isolates were compared with a set of random mucoid isolates, 20 of 52 (38%) nonmucoid isolates were typable and serum resistant, compared with 13 of 51 (24%) mucoid isolates (P 0.16 by chi-square analysis). However, nonmucoid strains from CF patients colonized only with nonmucoid strains were more frequently typable and serum resistant (67%) than were nonmucoid isolates from patients cocolonized with mucoid strains (31%) (P = 0.012, Fisher exact test). An inhibition enzyme-linked immunosorbent assay done with bacterial extracts, a direct-whole-cell enzyme-linked immunosorbent assay done with aftinity-purified antibody to MEP, and immune electron microscopy all demonstrated production of MEP by all nonmucoid P. aeruginosa isolates tested, including nonmucoid revertants of mucoid strains. No other bacterial species tested positive in these assays. These Sfndings suggest that MEP is produced by all P. aeruginosa isolates obtained from CF patients, that the initial colonizing nonmucoid strains produce a smooth LPS, and that once LPS-rough, mucoid strains appear in the sputum, the predominant LPS phenotype is rough regardless of colony morphology.
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Respiratory tract colonization of cystic fibrosis (CF) patients by bacterial pathogens is often associated with deterioration of pulmonary function and death resulting from pulmonary failure (5, 6) . The disease process has many curious aspects, including the propensity of a single pathogen, Pseudomonas aeruginosa, to be associated with pulmonary failure in most CF patients when they experience pulmonary failure (6, 7) , the physiology of the host (5, 6) , and the inability of host defenses to clear organisms despite potent immune responses to bacterial antigens (10, 27) . Another interesting aspect of the disease is the emergence of mucoid forms of P. aeruginosa after initial colonization with nonmucoid organisms (11) . Mucoid strains produce an extracellular antigen, mucoid exopolysaccharide (MEP), and are usually serum-sensitive, lipopolysaccharide (LPS)-rough isolates (9, 17, 19) . Little is known, however, about the surface antigen expression of the initial colonizing nonmucoid strains.
Information about the antigens expressed by nonmucoid isolates that initially colonize CF patients is important in understanding the pathogenesis of P. aeruginosa in CF patients and in developing vaccine strategies to prevent chronic colonization. Several investigators (20, 29) The major surface antigens of P. aeruginosa include LPS, high-molecular-weight polysaccharide (21) , pili (18) , flagella (12) , outer membrane proteins (8) , and possibly MEP (22) . Because several studies (10, 27) have shown that the P. aeruginosa surface polysaccharides have an important role in CF pathogenesis, we analyzed morphologically nonmucoid isolates obtained from CF sputum cultures, including strains isolated from patients colonized only with nonmucoid strains, for the production of serotype antigens (expressed on LPS and high-molecular-weight polysaccharide) and MEP. In addition, we analyzed the sensitivity to normal human serum of these nonnucoid isolates as a correlate of the production of smooth LPS (9) . Susceptibility to killing by <10% normal human serum has been shown to be a property of LPS-rough strains of P. aeruginosa (9, 17) . We were interested in determining whether all nonmucoid isolates were different from mucoid isolates in the expression of serotype antigens, or whether nonmucoid isolates from patients colonized only with nonmucoid strains had a different expression of serotype antigens compared with nonmucoid isolates obtained from patients cocolonized with mucoid P. aeruginosa. For comparison, we used random mucoid isolates of P. aeruginosa from CF patients in two cities. As expected, these strains were similar to previously described strains (9) in serotype antigen expression and serum sensitivity. We also determined whether nonmucoid strains produced MEP and whether there was any difference between production of MEP by isolates from patients colonized only with these strains and isolates from patients cocolonized with mucoid strains.
MATERIALS AND METHODS
Bacterial strains. Mucoid and nonmucoid P. aeruginosa strains from sputum cultures of CF patients were isolated in the microbiology laboratories at Children's Hospital, Bos- Antigens and antisera. Purified MEP from P. aeruginosa 2192 and rabbit antisera to this antigen were prepared as described previously (22) . Affinity-purified antibody to MEP was prepared as described previously (1) by using MEP bound to epoxy-activated Sepharose as an affinity column.
Serotyping and serum sensitivity. Serotyping by agglutination was performed as described previously (23) (23) . Sensitivity to 5% normal human serum was also tested as described previously (9) 
RESULTS
Serotypes and serum sensitivity of P. aerugmnosa isolates.
The serotype distribution and serum sensitivity patterns of all nonmucoid P. aeruginosa isolates obtained from CF patients were compared with data from a set of mucoid isolates obtained from patients seen in the CF clinic at the same time (Table 1) . Thirteen of 51 (26%) mucoid strains were both serotypable and serum resistant, compared with 20 of 52 (38%) nonmucoid strains (P = 0.16, chi-square analysis). Twenty-three of 51 (46%) mucoid strains were both nontypable and serum sensitive, compared with 20 of 52 (38%) nonmucoid strains (P = 0.49, chi-square analysis). Thus, there were no readily discernible differences between mucoid and nonmucoid P. aeruginosa isolates in nontypability or serum sensitivity, dual properties of LPS-rough strains.
Previous investigators (2, 28) suggested that there are no major phenotypic differences between mucoid and nonmucoid P. aeruginosa isolates from the same patient, with the obvious exception of mucoid growth. To determine whether nonmucoid isolates obtained from CF patients colonized only with nonmucoid strains were different from nonmucoid isolates obtained from patients cocolonized with mucoid strains, we compared the serotypes and serum sensitivities of the two groups. As determined by a review of clinical records, the median length of bacterial colonization for patients harboring only nonmucoid isolates (3.2 months) was significantly shorter (P < 0.001, Mann-Whitney U Test) than the median length of bacterial colonization of patients harboring mucoid isolates as well (35 months). In fact, the nonmucoid strains obtained from 17 of 24 CF patients harboring only nonmucoid strains came from the first sputum culture positive for P. aeruginosa, suggesting that most nonmucoid strains represented the initial colonizing P. aeruginosa strain from these patients. The serotype distribution and serum sensitivity of nonmuoid isolates from patients harboring only nonmucoid strains were then compared with that of nonmucoid isolates from patients cocolonized with mucoid strains ( 6) were documented among the isolates from patients harboring only nonmucoid strains. The implication of this finding cannot be fully determined because these strains came from patients in only one area (Boston, Mass.). Thus, strains from patients harboring only nonmucoid isolates were significantly more likely to be serotypable and serum resistant than were nonmucoid isolates from patients cocolonized with mucoid P. aeruginosa.
Expression of MEP by nonmucoid isolates. We tested the nonmucoid isolates for expression of MEP by the two serologic methods described in Materials and Methods. Extracts of nonmucoid strains from patients colonized only with these isolates, as well as extracts of nonmucoid strains from patients also harboring mucoid isolates, contained high levels of MEP (Table 3 ). There was no significant difference (P > 0.05, Mann-Whitney U test) between the amounts of MEP produced by these two sets of nonmucoid isolates. Extracts prepared from a set of nonmucoid revertants derived from mucoid strains also contained high levels of MEP. All other bacterial species tested, including several P. cepacia strains from CF patients, yielded extracts that were negative for MEP.
The second serologic assay, which used an affinitypurified rabbit antibody to MEP to probe bacterial strains immobilized in ELISA plates, yielded positive antibody reactions with all nonmucoid isolates and nonmucoid revertants of P. aeruginosa, whereas all other bacterial species were negative (Table 3 ). This assay confirmed the results of the inhibition ELISA, showing that nonmucoid isolates of P. aeruginosa produce MEP.
Comparison of colorimetric and serologic assays for MEP. We next used the carbazole assay for uronic acids to quantitate MEP constituents in extracts from 12 nonmucoid P. aeruginosa strains. Of these 12 extracts, 10 were negative in the carbazole assay, and the mean micrograms of MEP per milliliter detected by carbazole was considerably lower than that detected by the inhibition ELISA (Table 4) . To determine whether extract constituents interfered with the carbazole assay, we added purified MEP (500 ,ug/ml) to extracts from five strains negative for MEP by the carbazole assay and measured the uronic acid content. A control containing 500 ,ug of alginic acid per ml in bacterial extracts was also tested. We found that only about 30% of the MEP or alginic acid was detected by the carbazole assay in the presence of bacterial extract ( Table 4 ), indicating that components of these extracts interfere in the colorimetric assay.
Visualization of MEP on mucoid and nonmucoid P. aeruginosa strains by immune electron microscopy. Electron micro- graphs of mucoid and nonmucoid strains treated with rabbit antiserum raised to purified MEP were taken to visualize the antigen on and around the bacterial cells. The micrographs of two mucoid strains and the nonmucoid revertant of one of them ( Fig. 1) showed an extracellular material reacting with the antiserum; the material was located near the bacterial surface and was much like a capsule. In addition, ferritin particles were seen bound to aggregates of intercellular debris, indicating the presence of MEP in the aggregates. Micrographs of three nonmucoid strains isolated from patients colonized only with nonmucoid strains showed that most of the material binding the ferritin label was located between the individual cells and was not tightly bound to the cell surface (Fig. 2) . This indicated that the MEP synthesized by the nonmucoid strains did not remain tightly bound to the bacterial surface but was released into the intercellular milieu. DISCUSSION The circumstances that predispose CF patients to colonization by P. aeruginosa are not well understood. The most critical factors likely reside within the host. Yet for CF patients P. aeruginosa is by far and away the most commonly encountered pathogen that leads to severe morbidity and ultimate mortality. Thus, pathogenic mechanisms unique to P. aeruginosa must be involved in the disease process. Because two morphologically different types of organism are routinely obtained from CF patients, we sought to determine whether these isolates were different in the expression of serotype antigens or resistance to normal human serum and whether nonmucoid isolates produced MEP. A number of studies (9, 17, 18) have shown that most (60 to 80%) mucoid isolates from CF patients are nontypable, serum sensitive, LPS-rough organisms. Our study extended these observations to nonmucoid isolates obtained from patients cocolonized with mucoid isolates. Our study also showed that when nonmucoid isolates were obtained from patients colonized only with these strains, they were usually serotypable, serum resistant, and, therefore, LPSsmooth organisms.
Because nonmucoid isolates from CF patients harboring only nonmucoid isolates (17 of 24 patients) were usually the first P. aeruginosa strains clinically obtained, our results suggest that the early colonizing strains phenotypically express a smooth LPS. When nonmucoid isolates were tested for the production of MEP, we were able to confirm the presence of MEP by two serologic assays and by immune electron microscopy. No other bacterial species tested positive for MEP in the serologic assays, implying the uniqueness of this antigen to P. aeruginosa. The serologic and electron microscopic demonstration of MEP production by nonmucoid P. aeruginosa was consistent with our previous finding that a nonmucoid strain can elicit rabbit antibody to MEP (22) . Interestingly, the electron micrographs showed that the differences in MEP production between mucoid and nonmucoid strains may not have been only quantitative but may also have involved the ability of mucoid strains to retain MEP on their surface. Nonmucoid strains appeared to release most of their MEP antigen into the intercellular milieu. The production of MEP by nonmucoid strains was also consistent with the finding of Woods and Bryan (29) that antibody to MEP was able to protect rats from chronic colonization with a nonmucoid P. aeruginosa strain.
Our data also showed that the traditional carbazole assay for uronic acids is not sensitive enough to detect MEP in extracts of nonmucoid strains. In fact, we showed that the addition of purified MEP or alginic acid to bacterial extracts resulted in the detection of only 30% of this material by the carbazole assay. Thus, caution must be exercised in describing a P. aeruginosa isolate as negative for MEP when the carbazole assay is used. In fact, the two extracts of nonmucoid strains that tested positive by the carbazole assay contained the highest amount of MEP that could be detected by the serologic test.
The finding that the nonmucoid strains obtained from CF patients harboring only nonmucoid strains were more likely to be LPS smooth implies that CF patients become colonized by exposure to P. aeruginosa strains commonly found in the environment. Furthermore, it is likely that the emergence of serum-sensitive, LPS-rough mucoid isolates results from selective pressures of the host, possibly including antibody or other immune responses. However, this conclusion can be supported only by a longitudinal study that characterizes serial P. aeruginosa isolates and sera from individual patients. The isolation of variant strains that are serotypable yet serum sensitive, as well as strains that are nontypable yet serum resistant (Tables 1 and 2 ), was consistent with the hypothesis that host responses to colonization put selective pressures on P. aeruginosa that result in the emergence of nontypable, serum-sensitive isolates. The variant strains appeared to represent an intermediate step between the early and later colonizing strains.
The finding that the early nonmucoid colonizing strains usually express serotype antigens raises the possibility that vaccines eliciting antibody to these antigens could protect CF patients. However, the data do not support this conclusion. First, a role for type-specific antigens in the pathogenesis of P. aeruginosa colonization of CF patients has not been established. Ramphal et al. (24) showed that nonmucoid P. aeruginosa adheres to acid-injured murine tracheal tissues via pili. This observation was recently extended to the adherence of nonmucoid strains to human tracheobronchial mucins (R. Ramphal, C. Guay, and G. B. Pier, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 111, 1985). Thus, antibody to serotype determinants likely will not prevent adherence. It is possible that type-specific antibody opsonizes bacteria for phagocytic killing. However, the predominant antibody of the upper respiratory tract, secretory IgA, cannot mediate the opsonophagocytic killing of P. aeruginosa (25) . Second, antibody to the International Antigenic Typing System serotype 1 determinant is almost universally present at high levels in the sera of normal adults and children, including CF patients not colonized by P. aeruginosa (unpublished observation). This serotype was the most common one among our typable strains, suggesting that the presence of antibody to this determinant is not protective. Third, Langford and Hiller (14) recently completed a trial of a P. aeruginosa vaccine in noncolonized CF patients that failed to demonstrate protection against colonization. This vaccine was recently characterized, and its active components appear to be type-specific antigens, such as LPS (15) . Fourth, preliminary data from our laboratory (G. B. Pier and J. Saunders, Clin. Res. 33: 415A, 1985) , indicate that older (>15 years) CF patients who have escaped colonization by P. aeruginosa all have high levels of opsonophagocytic killing antibody directed at MEP and not against serotype antigens. This finding is consistent with the demonstration that al! nonmucoid isolates from CF patients express MEP. Studies are under way to determine whether antibody to MEP can mediate the opsonophagocytic killing of nonmucoid strains.
These results on surface polysaccharide antigens expressed by nonmucoid P. aeruginosa isolates should contribute to our understanding of'the interaction between this organism and CF patients. The differences between the initial colonizing nonmucoid strains and the strains isolated later in the disease process imply a dynamic interaction of host and bacterial factors that allows chronic colonization to occur. A better understanding of these interactions could prove critical in the prevention and control of P. aeruginosa colonization of CF patients.
